| Platform Technology | Details | Applied/Registered | |
|---|---|---|---|
| M.MucoMax® | Cervical cancer | Stable constant high-manifestation vector for cervical cancer treatment vaccines and recombinant lactic acid bacteria that has been transformed by the vector |
Applied
|
|
Registered
|
|||
| Muscular dystrophy | Cell surface display vector that manifests myostatin and microorganisms that have been transformed by the vector |
Registered
|
|
| Fusion protein surface display vector of Myo-2 peptide composition, and myostatin and microorganisms that have been transformed by the vector |
Registered
|
||
| Manifestation (Promoter) |
New constant, high-manifestation promoter and its purpose of use |
Registered
|
|
| Transporter (PKV Vector) |
Constant high-manifestation vector containing repE rogue genes |
Registered
|
|
| Display | Surface display vector using γ-PGA synthetic genes originating from the Bacillus strain and the method of using this to manifest the surfaces of microorganisms of a protein |
Registered
|
|
| H.HumaMax® | CIN1 | Use of γ-PGA in the treatment of cervical epithelium dysmorphia |
Applied
|
| Vaccine adjuvant | Immunoadjuvant composition containing γ-PGA and keto acid nanoparticles |
Applied
|
|
| Vaccine containing either γ-PGA-keto acid-sM2HA2 nanoparticles or γ-PGA-keto acid-sM2HA2CTA1 nanoparticles |
Applied
|
||